← Leaderboards
Flavia Pichiorri
Ohio State University
$3,617,059
Attributed
$9,985,377
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,985,377 · 4
By mechanism
R01$9,985,377 · 4
Top collaborators
- Craig C. Hofmeister13 shared
- Mitch A Phelps7 shared
- Russell Christian Rockne5 shared
- John E. Shively5 shared
- Xiuli Wang5 shared
- Steven Terry Rosen4 shared
- Michael Rosenzweig4 shared
Most similar at Ohio State University
Same institution · by research overlap
- Craig C. Hofmeister$2,792,841
- Mitch A Phelps$6,387,631
- William James Waldman$2,683,316
- David P Carbone$20,647,321
- Jennifer A. Woyach$6,733,332
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsRelapseIn VivoPreclinical StudyToxic EffectMultiple MyelomaCancer CellBone MarrowMalignant NeoplasmsResistanceHematopoietic NeoplasmsPlasma CellsNeoplastic CellNovel TherapeuticsBasePharmaceutical PreparationsResponseFda ApprovedEpigenetic ProcessPublishingImmunePre-ClinicalReportingCell Surface
Grant awards (22)
Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans$677,645
R01 · FY2025 · CA
Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans$653,591
R01 · FY2023 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$394,548
R01 · FY2023 · CA · contact PI
Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans$656,771
R01 · FY2022 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$394,548
R01 · FY2022 · CA · contact PI
Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans$718,916
R01 · FY2021 · CA
Reolysin-based combination therapy in relapsed multiple myeloma$532,313
R01 · FY2021 · CA · contact PI
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2021 · CA · contact PI
Reolysin-based combination therapy in relapsed multiple myeloma$539,126
R01 · FY2020 · CA · contact PI
Overcoming IMiD resistance in Myeloma$478,259
R01 · FY2020 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2020 · CA · contact PI
Reolysin-based combination therapy in relapsed multiple myeloma$528,516
R01 · FY2019 · CA · contact PI
Overcoming IMiD resistance in Myeloma$443,589
R01 · FY2019 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2019 · CA · contact PI
Overcoming IMiD resistance in Myeloma$70,589
R01 · FY2019 · CA
Reolysin-based combination therapy in relapsed multiple myeloma$574,645
R01 · FY2018 · CA · contact PI
Overcoming IMiD resistance in Myeloma$468,343
R01 · FY2018 · CA
Overcoming IMiD resistance in Myeloma$468,343
R01 · FY2017 · CA
Reolysin-based combination therapy in relapsed multiple myeloma$535,679
R01 · FY2016 · CA · contact PI
Overcoming IMiD resistance in Myeloma$487,331
R01 · FY2016 · CA
Overcoming IMiD resistance in Myeloma$135,056
R01 · FY2016 · CA
Reolysin-based combination therapy in relapsed multiple myeloma$19,769
R01 · FY2016 · CA